Conversely, bosentan (ETA/ETB antagonist) [79], ambrisentan (ETA selective antagonist) [80], and macisentan (ETA/ETB antagonist) [81], which are orally administered, are approved in many countries for the treatment of pulmonary arterial hypertension. This evidence concerns the gene EDNRB and pulmonary arterial hypertension.